Immune surveillance reactivation to improve overall survival in small cell lung cancer (SCLC)

• Verfasst von: Thomas, Michael [VerfasserIn]
• Titel: Immune surveillance reactivation to improve overall survival in small cell lung cancer (SCLC)
• Titelzusatz: The randomized IMPULSE study
• Verf.angabe: M. Thomas, R. Carter, S. Ponce Aix, J. Riera-Knorrenschild, A. Navarro Mendivil, M. Domine, J. Kollmeier, P. Sadjadian, R.M. Huber, M. Wolf
• Fussnoten: Gesehen am 15.11.2017
• Titel Quelle: Enthalten in: Annals of oncology
• Jahr Quelle: 2016
• Band/Heft Quelle: 27(2016,Supplement 6) Artikel-Nummer 1432TiP
• ISSN Quelle: 1569-8041
• DOI: doi:10.1093/annonc/mdw389.10
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1565367286

Abstract

© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [e-mail]: The immune surveillance reactivator lefitolimod (MGN1703), a DNA-based Toll-like receptor 9 (TLR9) agonist, was compared to placebo in metastatic CRC (mCRC) patients with disease control after standard induction chemotherapy in the double-blind randomized phase 2 IMPACT study. Lefitolimod showed a superior effect over placebo in exploratory analyses of pretreatment characteristics that identified patients most likely to benefit from lefitolimod. A study in small cell lung cancer (SCLC) patients, IMPULSE, was designed to confirm this preliminary evidence of efficacy in a new, high-mortality-and-unmet-need indication.Trial design: Trial characteristics: IMPULSE is a randomized, international, multicenter, open-label trial to assess the effect of TLR9-mediated immune surveillance reactivation on overall survival (OS) in extensive-disease (ED) SCLC patients. Secondary endpoints include PFS, response rates, safety, and quality of...